IL27 and neoplasm: Our targeted IL-27 cytokine deploys a bispecific-anchored design to effectively target PCa tumor cells with the pepL module while inducing simultaneous anti-tumorigenic and pro-osteogenic responses through the pepL and IL-27p28 modules, respectively.